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Background: We investigated the immunohistochemical expression of p53, MAPK, topoisomerase II alpha (topoII
alpha) and Ki67 in ovarian serous carcinomas (OSCs) along with mutational analysis for KRAS and BRAF.
Methods: Eighty one cases of OSCs were reviewed and examined immunohistochemically using antibodies against
p53, MAPK, topoII alpha and Ki67. Staining was evaluated as a percentage of immunopositive cells with cut-off
levels at 10% for p53 and topoII alpha, and 5% for MAPK. The Ki67 immunoexpression was assessed by means of
Olympus Image Analysis System as a percentage of immunopositive cells in 1000 tumor cells. KRAS and BRAF
mutational analysis was performed on 73 available microdissected samples.
Results: Of 81 cases of OSCs 13.6% were of low-grade and 86.4% were of high-grade morphology. In the
high-grade group there was a significantly higher immunoexpression of p53 (P < 0.001) and topoII alpha (P = 0.001),
with Ki67 median 56.5 vs. 19 in low-grade group (P < 0.001). The difference in immunoexpression of active MAPK
between low- and high-grade group was also significant (P = 0.003). MAPK positive immunostaining was detected
in 63.6% of low-grade vs. 17.1% of high-grade OSCs. The frequency of KRAS mutation was significantly higher in
low-grade as compared to high-grade group (P = 0.006). None of the samples had BRAF mutation. In addition, we
detected positive MAPK immunoexpression in 13/59 samples with wild-type KRAS, suggesting that activation of
MAPK pathway is not ultimately related either to KRAS or BRAF mutation. Seven morphologically high-grade
samples (11.7%) showed both KRAS mutation and p53 immunopositivity.
Conclusions: Although this study is limited by its humble number of low-grade samples, our data fit the proposed
dualistic pathway of ovarian carcinogenesis. Mutational analysis for KRAS and BRAF discloses some possible
interactions between different tumorigenic pathways of low- and high-grade carcinomas. Immunohistochemical
staining for MAPK was not sufficiently sensitive, nor specific, to precisely predict the KRAS mutation. However, it
appears to be quite reliable in ruling out a KRAS mutation if the staining is negative.
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Hintergrund: Wir untersuchten die Immunohistochemische Expression der p53, MAPK, topoisomerase II alpha
(topoII alpha) und Ki67 in Ovarialkarzinomen (OSCs) anbei mit Mutationsanalyse für KRAS und BRAF.
Methode: 81 OSCs Fälle wurden analysiert und Immunohistochemisch untersucht mit Antikörper gegen p53,
MAPK, topoII alpha und Ki67. Die Färbung war ausgewertet als der Prozent von immunopositiven Zellen mit den
“cut-of” Niveau an 10% für p53 und topoII alpha und 5% für MAPK. Die Ki67 Expression war bewertet mittels
Olympus Image Analysis System als der Prozent von immunopositiven Zellen in 1000 Tumorzellen. KRAS and BRAF
Mutationsanalyse wurde in 73 verfügbaren microdissections Stichproben aufgeführt.
Ergebnisse: Von 81 OSCs Fälle 13.6% zeigte “low-grade” und 86.4% “high-grade”Morphologie. In der “high-
grade” Gruppe war eine statistisch bedeutende höhere Expression von p53 (P < 0.001) und topoII alpha (P = 0.001)
mit Ki67 median von 56.5 im Gegensatz zu 19 in der “low-grade” Gruppe (P < 0.001). Die Differenz in
Immunoexpression von aktiver MAPK zwischen der “low-grade” und “high-grade” Gruppe war statistisch bedeutend
(P = 0.003). MAPK positive Expression war in 63.6% der “low-grade” im Gegensatz von 17.1% der “high-
grade” Karzinoms bemerkt. Die Häufigkeit der KRAS Mutation war bedeutend höher in “low-grade” im Verglich zu
der “high-grade” Gruppe (P = 0.006). Keiner der Stichproben hate BRAF Mutation. Wir haben auch eine positive
MAPK Expression in 13/59 der Stichproben mit “wild-type” KRAS bemerkt, was sugeriert das die Aktivation des
MAPK Pfads ist nicht letztmalig mit KRAS oder BRAF verbunden. Sieben der “high-grade” Stichproben (11.7%) waren
KRAS Mutation und p53 Expression positive.
Schlussworte: Obwohl diese Studie mit bescheiden Nummer von “low-grade” Stichproben limitiert ist, unsere
Daten passen in das dualistische Modell von Ovarial Karzinogenesis. Mutationsanalyse für KRAS und BRAF enthüllen
einige mögliche Interaktionen zwischen verschieden tumorigenen Wege von “low”- and “high-grade” Karcinomen.
Die Immunohistochemische Expression für MAPK war nicht empfindlich oder spezifisch genüg um den KRAS
mutations Status des Tumor genau vorauszusagen.
Es scheint das die MAPK Expression ziemlich verlässlich ist in ausschließen der KRAS Mutation, wenn die Expression
negative ist.
Schlüsselwörter: Ovar, Seröse karzinome, Karzinogenesis, Typ I tumoren, Typ II tumorenBackground
In the Western hemisphere ovarian carcinomas still remain
the most frequent cause of death due to gynecological can-
cer [1]. Efforts in early detection and new insights in thera-
peutic approaches demonstrated no clear benefit. In a
sense, we are forced to go “back to basics”.
Historically, the principal means of classifying ovarian
carcinomas has been histological assessment of cell type.
This approach is reflected in the current World Health
Organization’s ovarian carcinoma classification [2]. Mean-
while, morphological studies upgraded by molecular genetic
studies have enabled new insights into the pathogenesis of
ovarian cancer with possible consequences on future cancer
screening and platinum-based treatments. It has become
apparent that the different subtypes of ovarian carcinoma
represent distinct disease entities.
The discovery of biological differences between low-
grade and high-grade serous carcinomas has provided a
basis for Baltimore group led by Robert J. Kurman to
propose a new dualistic model of ovarian carcinogenesis
that recognized “type I” and “type II” pathways, with
serous type ovarian carcinoma as a prototype [1,3].According to proposed model, ovarian serous carcin-
omas (OSCs) which evolve along type I pathway are rela-
tively indolent low-grade neoplasms that arise in a
stepwise fashion from well-characterized precursor lesions
and usually present as large FIGO stage I neoplasms. They
often harbor somatic mutations of genes encoding protein
kinases, including KRAS and BRAF, the upstream regula-
tors of mitogen-activated protein kinase (MAPK) [4].
According to Siedman et al. [5] low-grade serous carcin-
omas are significantly less common than high-grade and
represent approximately 10% of serous carcinomas.
In contrast, OSCs which evolve along type II pathway
are aggressive high-grade neoplasms, with a larger
volume of tumor occurring outside the ovaries. More
than 75% of high-grade carcinomas harbor TP53 muta-
tions. Recent data suggest that these neoplasms arise
from intraepithelial carcinomas, the majority of which
have been detected in the tubal fimbriae [1,6].
The loss of wild type p53 as a transcriptional
suppressor may lead to unregulated or inappropriate
expression of topoisomerase II alpha (topoII alpha),
resulting in increased cell proliferation [7]. TopoII
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topology, repair and replication, coded by a single copy
gene on the locus q21of chromosome 17 [8,9]. It is a
cell-cycle-related protein, expressed in normal as well
as neoplastic cells in the S, G2 and M phase [8,10,11].
The immunoexpression of Ki67 antigen has become a
useful tool to determine the proliferative potential of a
tumor. Its high expression has been found to indicate a
poor prognosis in several cancers, including ovarian [12].
The gene for Ki67 protein is located on chromosome
10q25. Ki67 protein expression is strictly connected with
cellular cycle. This antigen appears in G1, S, G2 and M
cellular cycle phases, remaining in hide in G0 and early
G1 phase [13].
So far, it is not clear whether some high-grade serous car-
cinomas develop from low-grade tumors that follow type I
pathway. Dualistic model implies that the pathogenesis of
low- and high-grade carcinomas is separate and independ-
ent. Nevertheless, according to Dehari et al. [14] there can
be rare intersections between these tumorigenic pathways.
The aim of this study was to better define ovarian
serous carcinomas and their relation to type I and type
II pathways, by comparing the p53, MAPK, topoII
alpha, and Ki67 immunohistochemical expression in
low- and high-grade morphological group along with
mutational analysis for KRAS and BRAF.
Methods
Tumor samples were obtained from the primary sur-
gery material prior to chemotherapy. Formalin-fixed,
paraffin-embedded tumor tissue samples of 81 OSCs
were retrieved from the archives of the Department of
Pathology, Clinical Hospital Center Split and classified
as low-grade or high-grade serous carcinomas accord-
ing to criteria proposed by Kurman and Shih [3].
Low-grade group corresponds to invasive low-grade ser-
ous carcinomas, mostly characterized by micropapillary
and cribriform patterns, with small solid nests and cords
of relatively uniform cell population with small, rounded
nuclei (the degree of nuclear atypia qualifies as grade 1).
Mitotic activity is low. Psammoma bodies are often
present and there is no evidence of necrosis.
High-grade group corresponds to the usual type of
serous carcinoma with complex papillary and solid
patterns, and marked cytological atypia. Tumor cells
have large, pleomorphic nuclei, and many cells are
multinucleated (nuclear atypia grades 2 and 3). There is a
high level of mitotic activity, and abnormal mitotic figures
are frequent. Necrosis is a common feature [3,15,16].
All patients were staged according to the criteria of the
International Federation of Gynecology and Obstetrics
(FIGO) staging system [17].
Ethical commitee for biomedical research of the
Clinical Hospital Center Split and School of Medicineapproved that this research are in compliance with the
Helsinki Declaration (reference number 49-1/06).
Immunohistochemistry
The evaluation of the immunohistochemical staining
was performed independently by two authors with
special interest in gynecological pathology.
All procedures were performed according to the man-
ufacturers’ protocols, using the standard streptavidin-
biotin-peroxidase technique.
Paraffin 3–5 μm thick tissue sections were deparaffi-
nized in xylene and rehydrated in descending concentra-
tions of alcohol. To facilitate antigen retrieval, slides were
treated in a microwave oven at 750 W and 110°C, 3 times
for 5 minutes in a citrate buffer. Immunostainings for p53,
topoII alpha and Ki67 (clone MIB-1) were performed with
monoclonal antibodies to human p53 (DAKO, Glostrup,
Denmark, mouse anti-human M7001, at a dilution of
1:50), topoII alpha (DAKO, Glostrup, Denmark, mouse
anti-human 7816, at a dilution of 1:75) and Ki67 (DAKO,
Glostrup, Denmark, mouse anti-human M7240, at a dilu-
tion of 1:200). Immunostaining for MAPK was performed
with rabbit polyclonal antibody, pTEpY, which specifically
reacts with phosphorylated (active) MAPK (Promega,
Madison, WI, V8031, at a dilution of 1:500). All
slides were incubated with labeled streptavidin-biotin
followed by diaminobenzidin chromogen (DAKO).
Mayer′s hematoxylin was used for counterstaining.
Nuclear staining for p53, topoII alpha and Ki67 was
considered as a positive result. Positive reaction for MAPK
was defined as discrete localization of the brown chromo-
gen in the nucleus or cytoplasm. Negative controls were
created by omission of the primary antibody.
Staining was evaluated according to the number of
cells showing positivity (as a percentage of positive
cells), within representative areas of the tumor sample.
For statistical analysis, based on reports in the published
literature, cut-off levels were stratified at 10% for p53
[18] and topoII alpha [9] and 5% for MAPK [19].
The Ki67 immunoexpression was assessed by means
of Olympus Image Analysis System as a percentage of
immunopositive cells in 1000 tumor cells.
Mutational analysis
Paraffin blocks from 73 cases were available for molecular
analysis. Genomic DNA was isolated using a High Pure
PCR Template extraction kit (Roche Applied Science,
Germany), according to the manufacturer’s protocol.
PCR analysis and determination of KRAS and BRAF
mutations
KRAS mutation detection in exon 1 codons 12 and 13 was
performed using LightMixW Kit k-ras Mutations Codons
12/13 (Roche Diagnostics, Germany) and LightCyclerW
Table 1 Clinicopathological features of patients with
OSCs
Low-grade High-grade P
(n = 11) (n = 70)
Age at diagnosis, yrs, median
(min-max)
52 (44–71) 63.5 (37–89) 0.028*
FIGO stage, n (%)
I-II 4 (36.4) 6 (8.6) 0.026†
III-IV 7 (63.6) 64 (91.5)
Mitotic activity, median
(min-max)
9 (1–12) 27 (13–65) < 0.001*
Vascular invasion, n (%)
No 10 (90.9) 20 (28.6) < 0.001†
Yes 1 (9.1) 50 (71.4)
Residual tumor, n (%)
No 7 (63.6) 12 (17.1) 0.019†
≤ 2 cm 1 (9.1) 14 (20.2)
≥ 2 cm 3 (27.3) 44 (62.9)
*Based on Mann–Whitney U test.
† Based on χ2 test.
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Germany). PCR was performed with LightCycler 2.0 instru-
ment (Roche Diagnostics, Germany), according to manu-
facturer’s recommendations.
Primers used for BRAF PCR amplification and PCR
conditions were those given in Powell et al. [20] PCR
was performed with GeneAmp PCR System 9700
(Applied Biosystems, Foster City, CA).
Statistical analysis
Statistical analysis was carried out using the SPSS version
10.0 software package. The categorical variables were
compared using χ2 test. Continuous variables were com-
pared using the Mann–Whitney U test. P values ≤ 0.05
were considered statistically significant.
Results
A total of 81 OSCs were included in this study.
According to previously described morphological cri-
teria, 13.6% (11/81) serous carcinomas in our study
were low-grade OSCs and 86.4% (70/81) were high-
grade OSCs.
Patients’ age ranged from 44–71 years in low-grade
(median, 52) and 37–89 (median, 63.5) years in high-
grade group. At diagnosis, 72.7% of patients in low-
grade and 47.1% of patients in high-grade group were
under the age of 60. There was no association between
the tumor group and the age of patient (χ2 = 1.5;
P = 0.194).
Seven of eleven (63.6%) patients in the low-grade
group and 64/70 (91.5%) patients in the high-grade
group had advanced stage disease (stages III or IV).
Therefore, 35.4% of the low-grade and merely 8.6% of
the high-grade carcinomas are discovered in the early
FIGO stages (χ2 = 4.5; P = 0.026).
After surgery, 63.6% patients from the low-grade
group and only 17.1% patients from the high-grade
group were without residual tumor. Residual tumor lar-
ger than 2 cm was still present in 62.9% of patients with
high-grade OSC, and 27.3% of patients with low-grade
OSC (χ2 = 9.9; P = 0.019). The presence of immeasurable
lesion (i.e. ascites) without solitary residual tumor was
detected in 28.6% of patients in the low-grade group,
and 16.7% of patients in the high-grade group.
Mitotic activity was determined as mitotic count on
10 high power fields (HPFs). Thirty-two percent of low-
grade carcinomas had ≤ 2 mitoses/10 HPFs. Median in
the low-grade group was 9 mitoses/10 HPFs (range, 1–
12). In the high-grade group, grade 2 nuclear atypia was
found in 31%, and grade 3 nuclear atypia in 69% of
carcinomas. Median in the high-grade group was 27
mitoses/10 HPFs (range, 13–65). Vascular invasion was
present in 71.4% of the high-grade and in only 9.1% of
the low-grade carcinomas (χ2 = 13.3; P < 0.001).Clinicopathological features are summarized in
Table 1.Immunohistochemical evaluation
All of the samples in the low-grade group (100%) exhib-
ited p53 nuclear staining lower than 10% (Figure 1A). In
the high-grade group, 85.7% of cases showed strong
positive nuclear expression of p53 protein (Figure 2A),
while 14.3% of cases showed less than 10% positive
nuclei. The observed difference in the p53 protein ex-
pression between these two categories was statistically
significant (P < 0.001).
The difference in expression of MAPK between low-
and high-grade group was also significant (χ2 = 9.0,
P = 0.003). MAPK positive staining was detected in
63.6% of low-grade (Figure 1B) as opposed to 17.1%
of high-grade carcinomas. The high-grade group is re-
presented with 82.9% of MAPK negative carcinomas
(Figure 2B). Ten out of 70 (14.3%) high-grade samples
showed simultaneous p53 and MAPK immunoexpression.
There was a significantly higher topoII alpha expres-
sion in the high-grade group (Figure 2C) compared to
the low-grade group (χ2 = 11.2, P = 0.001) (Figure 1C).
18.6% of the high-grade carcinomas exhibited less than
10% of positive nuclei.
Significant difference was also observed in the expres-
sion of Ki67 between the low- and the high-grade group
(z = 4.4, P < 0.001). In the low-grade group median was
19 (range, 7–54) as opposed to the high-grade group in
which median was 56.5 (range, 18–98) (Figure 1D and
Figure 2D).
Figure 1 Representative immunostaining patterns of low-grade OSCs. Negative p53 immunoexpression (A; original magnification, × 200),
positive MAPK immunoexpression (B; original magnification, × 200), negative topoII alpha immunoexpression (C; original magnification, × 200),
low Ki67 proliferative activity (D; original magnification, × 200).
Figure 2 Representative immunostaining patterns of high-grade OSCs. Strong p53 immunoexpression (A; original magnification, × 200),
negative MAPK immunoexpression (B; original magnification, × 200), positive topoII alpha immunoexpression (C; original magnification, × 200),
high Ki67 proliferative activity (D; original magnification, × 200).
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Table 3 Correlation of MAPK immunoreactivity and
mutational status of KRAS in low- and high-grade OSCs
Low-grade High-grade
(No. of cases) (No. of cases)
KRAS mutation
MAPK + 5 1
MAPK – 1 7
Wild KRAS
MAPK + 2 11
MAPK – 3 43
Total cases 11 62
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shown in Table 2. Representative immunostaining pat-
terns are summarized in Figure 1A-D for low-grade, and
Figure 2A-D for high-grade OSCs.
Molecular analysis
KRAS mutation was found in 54.5% of low-grade and
13.8% of high-grade OSCs. The frequency of KRAS mu-
tation was significantly higher in low-grade as compared
to high-grade group (χ2 = 7.4, P = 0.006). None of the
samples had BRAF mutation. We identified seven
(11.7%) high-grade samples that showed both KRAS
mutation and p53 immunopositivity.
Furthermore, we compared the findings of KRAS mu-
tational analysis with active MAPK immunoreactivity.
As shown in Table 3, the relationship between immu-
noreactivity and KRAS status is not statistically strong
enough to use immunoreactivity to reliably detect KRAS
mutation. We observed that 5/6 (83%) of low-grade and
1/8 (12.5%) of high-grade MAPK immunopositive car-
cinomas contained KRAS mutation. Also, 2/5 (40%) of
low-grade and 11/54 (20.4%) of high-grade carcinomas,
with wild-type KRAS, showed MAPK positivity. There-
fore, MAPK immunopositivity has only limited value in
predicting KRAS mutations, with a sensitivity of 0.43, a
specificity of 0.78, a positive predictive value of 0.32,
and a negative predictive value of 0.85.
Discussion
Currently, low-grade and high-grade serous carcinomas
are thought to represent two distinct pathways of ovar-
ian carcinogenesis, rather than opposite ends of severity
along a single trajectory of tumor progression. Recent
studies have convincingly demonstrated that morpho-
logical differences between these tumors are a mani-
festation of their underlying biological and geneticTable 2 Immunohistochemical staining results of p53,
MAPK, topoIIα and Ki67 expression in OSCs
Low-grade High-grade P
(n = 11) (n = 70)
p53, n (%)
negative 11 (100) 10 (14.3) < 0.001†
positive 0 (0) 60 (85.7)
MAPK, n (%)
negative 4 (36.4) 58 (82.9) 0.003†
positive 7 (63.6) 12 (17.1)
topoII alpha, n (%)
negative 7 (63.6) 13 (18.6) 0.001†
positive 4 (36.4) 57 (81.4)
Ki67, median (min-max) 19 (7–54) 56.5 (18–98) < 0.001*
†Based on χ2 test.
*Based on Mann–Whitney U test.disparity. Briefly, low-grade carcinomas evolve along
type I pathway and represent relatively indolent neo-
plasms that arise in a stepwise fashion from well-
characterized precursor lesions. High-grade carcinomas
are aggressive, genetically unstable neoplasms that arise
through type II pathway. However, it remains an open
issue whether some high-grade serous carcinomas arise
from low-grade serous carcinomas that follow type I
pathway [3,4,21].
The proposed dualistic model has important implica-
tions for early detection and targeted treatment. Current
screening approaches, namely pelvic examinations, CA
125 levels and transvaginal ultrasound are reasonable for
low-grade carcinomas, but are not likely to be sufficiently
beneficial for high-grade carcinomas. Although the man-
agement of these two groups is currently identical, the
growing body of evidence suggests that low-grade serous
carcinomas are not as responsive as high-grade serous car-
cinomas to conventional chemotherapy with platinum
and taxane agents [22-24].
A better understanding of the molecular patho-
genesis of low-grade serous carcinomas would lead to
rational evaluation of new targeted agents for the treat-
ment of this disease. Reports point towards a high
frequency of KRAS and BRAF mutations in low-grade
OSCs, making this pathway an attractive therapeutic
target by interfering with its downstream effectors
[25,26]. The preliminary promising results of a phase II
clinical trial evaluating AZD6244 (selumetenib), an
inhibitor of MEK-1/2, have been reported [27].
We report our findings of the immunohistochemical
expression of p53, MAPK, topoII alpha and Ki67, and
molecular analysis for KRAS and BRAF mutations in the
OSCs.
p53 is a tumor suppressor gene located on the short
arm of chromosome 17, involved in regulation of cell
growth [28]. Despite compelling evidence for the cen-
tral role of the p53 pathway in human neoplasia, the
assessment of p53 status in clinical samples remains
unanswered, with confusing and often contradictory
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terpretation of the staining results in different studies
further contribute to the confusion [18,28-30]. While
the correlation between p53 mutational status and
immunohistochemical expression is suboptimal, differ-
ences in the immunoexpression of p53 in low- and
high-grade carcinomas can be diagnostically useful.
There have been a few studies investigating the p53
immunoreactivity in low- and high-grade OSCs [28,31].
In these studies, the extent of immunoexpression was
significantly different between low- and high-grade
carcinomas (16.7% vs. 53.6%, and 18% vs. 64% of cases
exhibited strong staining intensity). Our study confirms
significantly higher p53 immunoexpression in the high-
grade group (85.7% high-grade carcinomas showed >10%
positive cells). In a study by Mishra et al. [31] 22.2% of
low-grade samples scored as 0 and 1+ (negative or <10%
positive cells). Unlike Mishra’s study, none of our low-
grade samples showed more than 10% of p53 immuno-
positive nuclei.
There is no definitive proof that all low-grade OSCs
arise in a stepwise fashion from well-characterized
precursor lesions and it is possible that some do not.
Likewise, on rare occasions, a low-grade OSC may
transform into a high-grade neoplasm [32]. Several
studies have shown that, in rare cases, low- and high-
grade serous tumors do coexist and/or high-grade
serous carcinomas share similar gene expression profile
as low-grade carcinomas [14,33].
Therefore, we upgraded the basic morphology and
p53 immunoexpression with added MAPK, topo II
alpha and Ki67 analysis.
MAPK is a downstream target of the RAS, RAF and
MAP/ERK kinases, and is crucial for transduction of
growth signals from several key growth factors, cyto-
kines and proto-oncogenes. Mutations (including KRAS
and BRAF) or overexpression of upstream components
in signal transduction cascades, lead to constitutive acti-
vation of MAPK pathway [19]. Because of the frequent
KRAS or BRAF mutations in serous tumors that follow
type I pathway [3], we examined whether there would
be a differential immunoexpression of activated MAPK
in our low- and high-grade group.
Nucleocytoplasmic distribution of MAPK is a pivotal
point in regulation of its downstream targets. Dual
phosphorylation of MAPK on tyrosine and threonine
occurs in the cytoplasm. Activated MAPK must translo-
cate into the nucleus to phosphorylate nuclear targets.
Active form freely diffuses as a monomer through
nuclear pores, homodimerizes and enters the nucleus
via a carrier-free/nuclear pore-independent mechanism
or interacts with the nuclear pore complex for entry.
The nucleus has been proposed to act as an “anchoring
and inactivating center” were signal must be terminatedby dephosphorylation [34]. We found nuclear and cyto-
plasmic MAPK in almost all positive samples, which is
consistent with previous reports [19,35]. We did not
find any difference in localization of positive staining
between low- and high-grade group.
In the present study we stated that the immuno-
expression of activated MAPK was significantly higher in
low-grade as compared to high-grade serous carcinomas.
Although the literature on MAPK immunoexpression in
serous ovarian tumors is quite limited, our results support
findings reported by Hsu et al. [19].
We compared the findings of KRAS mutational ana-
lysis with active MAPK immunoreactivity. In this study,
frequency of KRAS mutation was significantly higher in
low-grade as compared to the high-grade group. Inter-
estingly, none of our OSC samples had BRAF mutation.
Similar findings were reported by Wong et al. [36], who
detected BRAF mutation in only 2%, and KRAS muta-
tion in 19% of low-grade OSCs. In contrast to our study,
they did not detect KRAS or BRAF mutations in their
high-grade group. We detected positive MAPK immu-
noexpression in some low- and high-grade samples with
wild-type KRAS, suggesting that activation of MAPK
pathway is not ultimately related to KRAS or BRAF
mutations.
Seven morphologically high-grade samples (11.7%)
showed KRAS mutation, characteristic for type I path-
way and p53 immunopositivity, hallmark of type II path-
way. However, due to the low number of cases, we
refrain from giving a definitive answer to open issues
and urge further investigation.
According to our results, unlike the ones of Hsu
et al. [19], MAPK immunostaining was not sufficiently
sensitive, nor specific, to precisely predict the KRAS
mutational status of the tumor. However, MAPK
immunostaining appears to be quite reliable in ruling
out a KRAS mutation if the staining is negative.
Immunohistochemical expression of topoII alpha in
ovarian carcinomas has been demonstrated in several
studies, but the results of these studies are difficult to
compare because the methodology and criteria for
evaluation varied greatly [8,9,37,38]. According to
studies on OSCs performed by Brustmann [8,38], the
topoII alpha labeling index (LI) increased with mitotic
activity (P < 0.0004), tumor grade (P = 0.0303), FIGO stage
(P = 0.0076) and indicates poor prognosis (P = 0.0182). To
the best of our knowledge, no study compared different
topoII alpha immunoexpression with regard to proposed
dualistic model of ovarian serous carcinogenesis. Based on
our results, we report a significantly higher topoII alpha
expression in the high-grade group compared to the low-
grade group (P = 0.001).
As expected, we identified a significant difference be-
tween Ki67 immunoexpression in the low-grade and the
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agreement with previous studies by O’Neill et al. [28]
and Mishra et al. [31]. Both groups have shown a lower
Ki67 proliferation index in low-grade compared to high-
grade OSCs.
The distinction between low- and high-grade serous
carcinoma may occasionally be a differential diagnostic
problem. Some high-grade serous carcinomas have
been shown to mimic low-grade serous carcinomas
architecturally. Many of these carcinomas have grade 2
nuclear atypia [21]. Our results indicate that morpho-
logically problematic serous carcinomas with markedly
elevated Ki67 proliferation index and positive topoII
alpha immunoexpression, are more likely to follow the
type II pathway and these markers could be a useful
additional tool in distinguishing the low- and high-
grade groups of OSCs, along with nuclear atypia and
mitotic count.
The findings of our study mostly support the proposed
dualistic model of ovarian carcinogenesis. However, mor-
phological examination combined with immunohisto-
chemistry and molecular analyses reveal rare intersections
between type I and type II tumorigenic pathway.
Conclusions
Although this study is limited by its humble number of
low-grade samples, our data fit the proposed dualistic
pathway of ovarian carcinogenesis. We found statisti-
cally significant differences in the immunohistoche-
mical expression of p53, MAPK, topo II alpha and
Ki67 between low- and high-grade ovarian cancers
along with differences in KRAS mutational status.
Immunohistochemical staining for MAPK was not suf-
ficiently sensitive, nor specific, to precisely predict the
KRAS mutational status of the tumor. However, it
appears to be quite reliable in ruling out a KRAS muta-
tion if the staining is negative. Also, mutational
analysis for KRAS and BRAF discloses some possible
interactions between type I and type II pathway and
could be useful in detection of small proportion of
high-grade carcinomas arising through type I pathway,
with possible diverse clinical behavior and specific
therapy requirements. Those patients might be consid-
ered for Ras-Raf-MEK-MAPK-targeting therapies on
the basis of molecular profiling data.
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